NeoGenomics, Inc. (NASDAQ:NEO) Shares Purchased by Mitsubishi UFJ Asset Management UK Ltd.

Mitsubishi UFJ Asset Management UK Ltd. boosted its holdings in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 16.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 56,000 shares of the medical research company’s stock after buying an additional 8,000 shares during the quarter. Mitsubishi UFJ Asset Management UK Ltd.’s holdings in NeoGenomics were worth $923,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of NEO. Moody National Bank Trust Division increased its position in NeoGenomics by 20.2% during the 4th quarter. Moody National Bank Trust Division now owns 73,226 shares of the medical research company’s stock worth $1,207,000 after purchasing an additional 12,314 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of NeoGenomics by 2.8% during the fourth quarter. Nordea Investment Management AB now owns 77,534 shares of the medical research company’s stock worth $1,301,000 after buying an additional 2,125 shares in the last quarter. Versant Capital Management Inc raised its position in shares of NeoGenomics by 174.9% in the fourth quarter. Versant Capital Management Inc now owns 1,795 shares of the medical research company’s stock valued at $30,000 after buying an additional 1,142 shares during the last quarter. Franklin Resources Inc. lifted its stake in shares of NeoGenomics by 2.0% during the third quarter. Franklin Resources Inc. now owns 2,043,840 shares of the medical research company’s stock valued at $28,225,000 after buying an additional 39,740 shares during the period. Finally, Geode Capital Management LLC grew its stake in NeoGenomics by 1.2% in the 3rd quarter. Geode Capital Management LLC now owns 3,051,806 shares of the medical research company’s stock worth $45,022,000 after acquiring an additional 36,136 shares during the period. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at NeoGenomics

In other news, General Counsel Alicia C. Olivo sold 5,175 shares of NeoGenomics stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $15.36, for a total transaction of $79,488.00. Following the sale, the general counsel now directly owns 37,129 shares of the company’s stock, valued at approximately $570,301.44. The trade was a 12.23 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.30% of the company’s stock.

NeoGenomics Stock Down 0.2 %

Shares of NASDAQ NEO opened at $14.18 on Wednesday. The stock has a fifty day moving average price of $16.64 and a 200 day moving average price of $15.68. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. NeoGenomics, Inc. has a 12-month low of $12.13 and a 12-month high of $19.11. The company has a market cap of $1.82 billion, a P/E ratio of -23.25 and a beta of 1.24.

NeoGenomics (NASDAQ:NEO) last posted its earnings results on Tuesday, November 5th. The medical research company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.01 by $0.04. The business had revenue of $167.80 million during the quarter, compared to analyst estimates of $167.00 million. NeoGenomics had a negative return on equity of 2.11% and a negative net margin of 12.07%. The company’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same quarter last year, the firm earned ($0.06) earnings per share. Research analysts anticipate that NeoGenomics, Inc. will post -0.16 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on the company. Jefferies Financial Group began coverage on NeoGenomics in a research report on Tuesday, December 10th. They set a “buy” rating and a $22.00 target price on the stock. Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research report on Monday, January 13th. Bank of America upped their price target on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $19.00 price target on shares of NeoGenomics in a report on Friday, January 10th. Two equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $20.30.

NeoGenomics Profile

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.